Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Popular GLP-1 medications like semaglutide and tirzepatide have been linked to rare vision issues, including NAION, raising ...

STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates.The outlook appeared ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...